BIOLINERX LTD. | Sales 2024 * | 17.57M 1.47B | Sales 2025 * | 29.87M 2.49B | Capitalization | 58.24M 4.86B |
|---|---|---|---|---|---|
| Net income 2024 * | -35M -2.92B | Net income 2025 * | -16M -1.33B | EV / Sales 2024 * | 3.31 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.95 x |
| P/E ratio 2024 * |
-2.43
x | P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioLineRX Ltd.
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 63 | 24/09/24 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 01/09/01 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 01/17/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 24/14/24 |
Avraham Molcho
BRD | Director/Board Member | 66 | 01/10/01 |
Aharon Schwartz
CHM | Chairman | 80 | 01/04/01 |
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Calendar
07/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
